Caplacizumab as a pre-emptive therapy in thrombotic thrombocytopenic purpura: A proactive strategy to reduce morbidity

Caplacizumab in Immune-Mediated Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Literature Review and Meta-Analyses of Clinical Trials and Observational Studies

Effectiveness of Adjunctive Caplacizumab Treatment in Immune Thrombotic Thrombocytopenic Purpura in Real-Life Setting. Retrospective Monocentric Cohort

Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)

Caplacizumab Therapy in Immune Thrombotic Thrombocytopenic Purpura

A Phase 3 Study to Evaluate the Efficacy and Safety of Caplacizumab without First-Line Therapeutic Plasma Exchange in Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

LONG-TERM OUTCOMES OF PATIENTS TREATED WITH CAPLACIZUMAB FOR IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP): THE POST-HERCULES STUDY

INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

Caplacizumab

Caplacizumab

NICE recommends caplacizumab for acute acquired TTP

Caplacizumab

Caplacizumab

Patients with acquired thrombotic thrombocytopenic purpura (TTP) have von Willebrand factor (VWF)–mediated platelet aggregates that consume platelets

Caplacizumab for TTP: A Temporizing Measure for a Relapsing Disease

Mortality from acquired thrombotic thrombocytopenic purpura (TTP) remains at 10% to 20%, despite treatment with plasma exchange and immunosuppression. Blocking the formation of vessel-occluding platelet aggregates by administering an inhibitor of von Willebrand factor might improve outcomes in this disorder. To examine the safety and efficacy of caplacizumab, a monoclonal antibody that binds to the von Willebrand factor and …